Skip to main content
December 2, 2022
Log In
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?
Log In
Don't have an account? Sign Up Here
Join Us
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's
Terms
and
Policy
Sign Up
Already have an account? Login here
Cyber Monday Deals on TheStreet Subscriptions
Cyber Monday Deals on TheStreet Subscriptions
Cyber Monday Deals on TheStreet Subscriptions
SUBSCRIBE
SUBSCRIBE
SUBSCRIBE
TECH
Retail
INVESTING
PERSONAL FINANCE
RETIREMENT
CRYPTO
MARKETS
ENTERTAINMENT
Premium Content
CATEGORIES
Tech
Retail
Crypto
Finance
Markets
Investing
Economics
Entertainment
Personal Finance
Breaking News
Video
TheStreet Deals
Newsletters
PREMIUM PRODUCTS
TheStreet Smarts
Action Alert Plus
Real Money
Crypto Investor
Real Money Pro
Quant Ratings
Retirement Daily
Top Stocks
Compare All
STREET NATION
ETF Focus
Retirement Daily
Apple Maven
Boardroom Alpha
Dividend Strategists
Amazon Maven
The Meme Stock
C-Suite Advisors
Sign In
Subscribe
Social Media
Elon Musk's Latest Twitter Move Looks Like an Act of Desperation
By Dan Weil
Retailers
AMZN
Amazon Needs to Kill Alexa, Maybe Exit Echo Devices
By Daniel Kline
Biotech
DMTK
Can DermTech Recover From Its 85% Tumble?
By Maxx Chatsko
Travel
RCL
Royal Caribbean Adds (Potentially) Controversial New Bar Idea
By Daniel Kline
Entertainment
DIS
Walt Disney Did Bob Chapek Dirty (Twice) and Did Iger no Favors
By Daniel Kline
Travel
CZR
MGM
Las Vegas Strip Failure Turns Into a Huge Win
By Daniel Kline
Travel
RCL
Royal Caribbean vs. Celebrity: Which Cruise Line Is Better?
By Daniel Kline
Retailers
WMT
TGT
COST
Amazon, Walmart, Target, and Costco Make Key Holiday Moves
By Daniel Kline
Retailers
TGT
WMT
AMZN
Target Stock: Why the Market Is Getting the Retailer Really Wrong
By Daniel Kline
TECHNOLOGY
Disney Follows Netflix in Making a Dumb Move (It's Worse for the Mouse)
By Daniel Kline
Biotech
Verve Therapeutics Crushed By Clinical Hold
By Maxx Chatsko
INVESTING
KRYS
Krystal Biotech Needs to Feed the Goldfish in 2023
By Maxx Chatsko
INVESTING
TMDX
TransMedics Is Crushing It. Are Investors Overpaying?
By Maxx Chatsko
REAL ESTATE
REITs Attractive After Sliding on Soaring Interest Rates
By Dan Weil
INVESTING
U.S. Wind Power Just Crossed an Important Milestone
By Maxx Chatsko
INVESTING
After Prime Medicine, What's the Next Gene Editing IPO?
By Maxx Chatsko
INVESTING
TXG
ILMN
Will 10x Genomics Disappoint Investors Again?
By Maxx Chatsko
INVESTING
Natural Gas Power Plants Begin Their Inevitable Decline
By Maxx Chatsko
TECHNOLOGY
Mark Zuckerberg, the Metaverse and Us
By Luc Olinga
INVESTING
Can Invitae Deliver a Positive Surprise?
By Maxx Chatsko
INVESTING
Patient Death in Alzheimer's Study May Limit Drug's Reach
By Maxx Chatsko
INVESTING
Exact Sciences Earnings: The Most Important Metric to Watch
By Maxx Chatsko
TECHNOLOGY
Amazon Briefly Leaves the $1 Trillion Club
By Luc Olinga
INVESTING
PTCT
BX
PTC Therapeutics Grabs Up to $1 Billion, but There's a Catch
By Maxx Chatsko
Analysis
CLOSE
CLOSE
CLOSE
CLOSE